Martin Mynarek
Overview
Explore the profile of Martin Mynarek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Funke V, Walter C, Melcher V, Wei L, Sandmann S, Hotfilder M, et al.
J Transl Med
. 2023 Jun;
21(1):363.
PMID: 37277823
Background: Cancer metabolism influences multiple aspects of tumorigenesis and causes diversity across malignancies. Although comprehensive research has extended our knowledge of molecular subgroups in medulloblastoma (MB), discrete analysis of metabolic...
22.
Obrecht D, Mynarek M, Stickan-Verfurth M, Bison B, Schuller U, Pajtler K, et al.
Klin Padiatr
. 2023 May;
235(3):167-177.
PMID: 37172610
Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way...
23.
Korshunov A, Okonechnikov K, Schrimpf D, Tonn S, Mynarek M, Koster J, et al.
Acta Neuropathol
. 2023 Apr;
145(6):829-842.
PMID: 37093271
Medulloblastoma (MB), one of the most common malignant pediatric brain tumor, is a heterogenous disease comprised of four distinct molecular groups (WNT, SHH, Group 3, Group 4). Each of these...
24.
Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, et al.
Nat Med
. 2023 Mar;
29(4):917-926.
PMID: 36928815
The large diversity of central nervous system (CNS) tumor types in children and adolescents results in disparate patient outcomes and renders accurate diagnosis challenging. In this study, we prospectively integrated...
25.
Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, et al.
Neuro Oncol
. 2023 Jan;
25(8):1518-1529.
PMID: 36715306
Background: The prognostic impact of clinical risk factors and DNA methylation patterns in sonic hedgehog (SHH)-activated early childhood desmoplastic/nodular medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN) were evaluated to...
26.
Cetin M, Rieckmann T, Hoffer K, Riepen B, Christiansen S, Gatzemeier F, et al.
Radiat Oncol
. 2023 Jan;
18(1):19.
PMID: 36709315
Background: The gene of the Epidermal growth factor receptor (EGFR) is one of the most frequently altered genes in glioblastoma (GBM), with deletions of exons 2-7 (EGFRvIII) being amongst the...
27.
Erker C, Mynarek M, Bailey S, Mazewski C, Baroni L, Massimino M, et al.
J Clin Oncol
. 2022 Dec;
41(10):1921-1932.
PMID: 36548930
Purpose: Infant and young childhood medulloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive late effects. Unfortunately, many children relapse. The purpose of this study was to...
28.
Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, et al.
Acta Neuropathol
. 2022 Dec;
145(1):97-112.
PMID: 36459208
Molecular groups of medulloblastoma (MB) are well established. Novel risk stratification parameters include Group 3/4 (non-WNT/non-SHH) methylation subgroups I-VIII or whole-chromosomal aberration (WCA) phenotypes. This study investigates the integration of...
29.
Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M, et al.
Acta Neuropathol
. 2022 Oct;
144(6):1143-1156.
PMID: 36181537
This study aimed to re-evaluate the prognostic impact of TP53 mutations and to identify specific chromosomal aberrations as possible prognostic markers in WNT-activated medulloblastoma (WNT-MB). In a cohort of 191...
30.
Korshunov A, Okonechnikov K, Stichel D, Schrimpf D, Delaidelli A, Tonn S, et al.
Acta Neuropathol
. 2022 Jun;
144(2):339-352.
PMID: 35771282
Medulloblastomas (MB) molecularly designated as Group 3 (Grp 3) MB represent a more clinically aggressive tumor variant which, as a group, displays heterogeneous molecular characteristics and disease outcomes. Reliable risk...